S2 Therapeutics, Inc.
http://
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From S2 Therapeutics, Inc.
Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways
BMS partners with Repertoire and Scenic, plus deals involving: G1/Pepper, Harmony/Epygenix, Biodexa/Emtora, Regeneron/Mammoth, Vertex/Treefrog and Immedica/KKR/Impilo.
Adalvo Celebrates Unique European Nod For Prolonged-Release Pregabalin
Adalvo, the B2B unit of the Alvo group of companies, has announced a successful decentralized European approval for its pregabalin prolonged-release tablets, with a launch imminent. The “milestone” for its value added medicines program could allow the firm to offer what it has previously billed as “the first once-daily pregabalin formulation.”
Sandoz US CCO Calls For Authorized Generic Omission From IRA
The Inflation Reduction Act should take a different approach when it comes to authorized generic products, Sandoz US chief commercial officer Tim DeGavre has told Generics Bulletin.
Why Sarepta’s Gene Therapy Trial Enrollment Has Been More Successful Than Its Other DMD Therapies
The EMBARK trial’s availability to more patients likely contributed to the much quicker enrollment than confirmatory trials for Exondys 51, Vyondys 53 and Amondys 45, which also saw enrollment targets and eligibility ages change over the years.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice